TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL

The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents, such as anti-CD19/CD3 bispecific T-cell engager b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Malik-Chaudhry, Harbani K., Prabhakar, Kirthana, Ugamraj, Harshad S., Boudreau, Andrew A., Buelow, Benjamin, Dang, Kevin, Davison, Laura M., Harris, Katherine E., Jorgensen, Brett, Ogana, Heather, Pham, Duy, Schellenberger, Ute, Van Schooten, Wim, Buelow, Roland, Iyer, Suhasini, Trinklein, Nathan D., Rangaswamy, Udaya S.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2021
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8023237/
https://ncbi.nlm.nih.gov/pubmed/33818299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2021.1890411
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados